Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-week National Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Trial in India to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone.

NCT01257412 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01257412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01257412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-week National Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Trial in India to Evaluate the Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Suspended
Start date
January 31, 2012
Completion date
June 30, 2013
Enrollment
375 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes